A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors

Roche

Status and phase

Terminated

Phase 1

Conditions

Neoplasms

Treatments

Drug: RG1507

Drug: RAD001

Study type

Interventional

Funder types

Industry

Identifiers

NCT00985374

NO21884

2008-005806-38

Details and patient eligibility

About

This 2 part study will assess the safety, tolerability and efficacy of a combination of oral daily RAD001 and intravenous 3-weekly R1507 in patients with advanced solid tumors. In Part 1 of the study, patients will be enrolled sequentially to receive 5mg by mouth (po) RAD001 daily + 16mg/kg intravenous (iv) R1507 every 3 weeks (level 1) and if tolerated, 10mg po RAD001 daily + 16mg/kg iv R1507 every 3 weeks (level 2).In Part 2 of the study, patients with 1) advanced renal cell cancer and 2) advanced pancreatic neuroendocrine tumors will receive the maximum tolerated dose regimen from Part 1 (5mg or 10mg po RAD001 + 16mg/kg iv R1507). The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.

Enrollment

11 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

adult patients, >=18 years of age;
histologically confirmed recurrent or refractory advanced solid tumor (Part 1);
advanced metastatic renal cell cancer OR advanced metastatic pancreatic neuroendocrine tumors, with evidence of progressive disease (Part 2);
measurable disease (Part 2);
ECOG performance status 0-2.

Exclusion criteria

prior treatment with agents acting via inhibition of IGF-IR pathway;
prior treatment with agents acting via inhibition of mTOR (Part 2);
untreated CNS metastases;
current anti-cancer therapy, or radiotherapy or chemotherapy <=4 weeks prior to enrollment;
other known malignancy requiring treatment.